Marathon's High-Priced Window May Not Stay Open Long

One Phase III trial hits but a second study misses by a mile.

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.